Compare IIIV & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | SABS |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.5M | 293.9M |
| IPO Year | 2018 | 2020 |
| Metric | IIIV | SABS |
|---|---|---|
| Price | $18.98 | $3.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $25.50 | $11.64 |
| AVG Volume (30 Days) | 283.3K | ★ 656.9K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $79.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $2.44 |
| 52 Week High | $30.09 | $5.15 |
| Indicator | IIIV | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 46.84 |
| Support Level | $18.47 | $2.44 |
| Resistance Level | $23.29 | $4.06 |
| Average True Range (ATR) | 0.60 | 0.24 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 79.65 | 48.60 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.